| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 150.67 | 149.00 |
| Gross Profit | 112.93 | 100.31 |
| Pretax Income | -18.48 | -28.20 |
| Net Income | -19.43 | -27.47 |
| Diluted EPS | -0.15 | -0.22 |
- Net Income YoY
- +29.3%
Key highlights
- Revenue reached $150.67 million, up from $149.00 million in the prior-year period
- Net loss narrowed by 29.3% to $19.43 million, compared to $27.47 million in Q3 2025
- Gross profit improved to $112.93 million from $100.31 million a year ago
- Full-year 2026 revenue guidance was raised to a range of $625 million to $635 million
- Booked orders for the Atera platform now exceed 50 instruments for the full year
How the Period Went
During the third quarter of 2026, 10x Genomics recorded revenue of $150.67 million, representing a slight increase over the $149.00 million reported in the same period last year. While the top-line growth was incremental, the company demonstrated significant progress in its path toward profitability. The net loss for the quarter narrowed to $19.43 million, a 29.3% improvement from the $27.47 million loss recorded in Q3 2025. This bottom-line recovery was driven by higher gross margins and disciplined expense management. Diluted loss per share also improved to $0.15, compared to a loss of $0.22 per share in the previous year's third quarter.
Margins and Profitability
Gross profit for the quarter rose to $112.93 million, up from $100.31 million in Q3 2025. This expansion in gross profit outpaced revenue growth, indicating a shift toward higher-margin products and manufacturing efficiencies. The company's pretax income also showed resilience, with the loss narrowing to $18.48 million from $28.20 million year-over-year. These gains come as the company scales its spatial biology offerings, which typically carry favorable margin profiles. Operating expenses were managed tightly to support the reduction in net losses, even as the company continued to invest in the commercialization of its newer platform technologies.
Business Overview
- Specializes in single-cell and spatial biology technologies for drug discovery and disease research
- Core platforms include Chromium for single-cell analysis and Visium/Xenium for spatial mapping
- Recently launched the Atera platform, with booked orders now exceeding 50 instruments for 2026
- Planned commercial launch of the Sentira Spatial cloud analysis platform in early 2027
- Primary customer base includes academic institutions, biotechnology firms, and pharmaceutical companies
Financial Context and Market Reaction
Despite the narrowing losses and raised full-year guidance, shares of 10x Genomics fell 14.01% following the announcement, reflecting broader volatility in the healthcare sector. The company's market capitalization stands at approximately $7.56 billion with a price of $58.06. Current technical indicators show a Relative Strength Index (RSI) of 37.4, placing the stock near the oversold boundary. While the stock has seen a 21.31% gain over the last quarter, it remains under pressure over the shorter term. Management's decision to raise full-year revenue guidance to between $625 million and $635 million suggests confidence in the fourth-quarter outlook.
Down 5.3% since our story on 6 Nov: $58.06 when we broke it → $54.99 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $69.89 |
|---|---|
| 20 Oct | $71.46 |
| 21 Oct | $75.59 |
| 22 Oct | $69.75 |
| 23 Oct | $71.55 |
| 26 Oct | $72.96 |
| 27 Oct | $78.02 |
| 28 Oct | $83.62 |
| 29 Oct | $81.55 |
| 30 Oct | $70.11 |
| 2 Nov | $61.63 |
| 3 Nov | $65.29 |
| 4 Nov | $67.52 |
| 5 Nov | $58.06 |
| 6 Nov | $59.28 |
| 9 Nov | $65.05 |
| 10 Nov | $62.90 |
| 11 Nov | $62.05 |
| 12 Nov | $59.10 |
| 13 Nov | $58.19 |
| 16 Nov | $54.99 |
Industry Landscape
The life sciences tools sector is currently defined by a competitive shift toward spatial biology, where 10x Genomics competes against major players like Bruker, which recently integrated NanoString, and Illumina. Market demand remains robust for high-resolution tissue profiling, although capital equipment spending in academic sectors has seen occasional fluctuations. 10x Genomics' focus on integrated hardware and software, such as the upcoming Sentira Spatial cloud platform, aims to differentiate its ecosystem from competitors. The company is scheduled to provide further strategic updates at the Jefferies Global Healthcare Conference in London on November 17, 2026.
| Date | Announcement | Amount |
|---|---|---|
| 05 Nov 2026 | Q3 2026 revenueSource: prnewswire.com | $150.7 Million |
| 05 Nov 2026 | Full-year 2026 revenue guidance raisedSource: stocktitan.net | – |
| 06 Aug 2026 | Q2 2026 revenueSource: stocktitan.net | $151.0 Million |
| 06 Aug 2026 | Full-year 2026 revenue guidance raisedSource: stocktitan.net | – |
| 07 May 2026 | Q1 2026 revenueSource: s28.q4cdn.com | $150.8 Million |
| 07 May 2026 | Full-year 2026 revenue guidance maintainedSource: prnewswire.com | – |
| Share price | $58.06 |
|---|---|
| Market cap | $7.6B |
| Revenue (annual) | $643M |
| 1-month price change | -28.02% |
| Sector | HealthcareMedical Devices |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by 10x Genomics, Inc. announcing its financial results for the third quarter ended September 30, 2026.
Track 10x Genomics, Inc. live
Get the next 10x Genomics, Inc. SEC filing seconds after it lands.



